NECANN New Jersey attracts over 5,000 industry leaders, features more than 200 exhibitors, and is ranked the 3rd largest B2B cannabis convention in the United States - positioning CBDL for unprecedented growth, revenue opportunities, and investor value.
Read More
Nearly 50 groups, including CatholicVote, are lobbying Trump to keep marijuana Schedule I - but where is that same passion for the patients? While faith leaders focus on fear, the DEA blocks MMJ BioPharma's FDA-approved clinical trials for Huntington's and Multiple Sclerosis, trapping science in an unconstitutional kangaroo court. This fight isn't about recreational weed - it's about whether America will allow DEA to stand between the sick and real medicine.
Read MoreWith 45-plus locations and more than 225 providers, the physician-owned practice makes it simpler for families to get all the appointments they need, while ensuring comprehensive, complete care.
Read MoreBreakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development program
U.S. New Drug Application filing for Rusfertide in polycythemia vera on track for Q4
Read More
From ‘Right to Try' to Cannabis: Trump's Next Breakthrough Could Unlock FDA Trials.
"President Trump's marijuana decision must go beyond politics-patients suffering from Huntington's disease and Multiple Sclerosis have waited nearly a decade for access to MMJ International Holdings' FDA-approved clinical trials. With capsules manufactured and science in place, all that's missing is the DEA stepping aside." stated Duane Boise, CEO MMJ International Holdings.
Read More
Following a landmark court ruling against the Department Of Labor, Duane Boise, CEO of MMJ International Holdings exposes the DEA's identical use of unconstitutional in house courts to paralyze medical cannabis research for Huntington's and Multiple Sclerosis patients.
Read MoreLeading Pharmaceutical Manufacturers, Contract Research Organizations, and Academic Medical Centers Collaborate on Global Research Project Using DistillerSR.
Read MoreCanalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally
Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Enrollment has reached approximately 25% in Jaguar's ongoing field study of Canalevia-CA1 in dogs
Read More
The Physician-Led Medical Group is Committed to Building Exceptional Partnerships and Enhancing Health in the Communities They Serve While Lessening the Burden of Care on Clinicians and Patients
Read More
VisiPure combines antioxidants and plant‑based compounds to support healthy circulation, protect against oxidative stress, and help maintain visual clarity for those experiencing eye fatigue and screen‑induced strain.
Read More
Enki Elixir supports clarity, energy, and natural balance-this guide explains how leading pineal‑support formulas work, compares top options, and shares expert analysis and user experiences.
Read More
neurocare's Apollo TMS Therapy systems are now FDA-cleared for the treatment of Obsessive Compulsive Disorder, offering a new non-drug treatment option for patients and providers.
Read More
"Two Federal Agencies, One Unconstitutional Playbook, all While Agency Overreach Crushes a 125 year old Family Farm and Paralyzes a Cannabis Cultivation Company for 7 years alike" says Duane Boise, CEO of MMJ International Holdings. DEA Administrator Terry Cole fix it!
Read MoreJaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar
Read More
